<DOC>
	<DOC>NCT01896869</DOC>
	<brief_summary>This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic tumor vaccine and patients who continue to receive FOLFIRINOX. Funding Source - FDA OOPD</brief_summary>
	<brief_title>A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion Criteria (abbreviated): 1. Documented adenocarcinoma of the pancreas 2. Stable metastatic pancreatic cancer after 812 doses of FOLFIRINOX 3. ECOG performance status of 0 or 1 4. Life expectancy greater than 3 months 5. Adequate organ and marrow function defined by studyspecified laboratory tests. 6. Must use acceptable form of birth control while on study 7. Oxygen saturation on room air &gt;92% Exclusion Criteria (abbreviated): 1. Surgery within 4 weeks of dosing investigational agent (some exceptions for minor procedures) 2. Off FOLFIRINOX treatment for more than 70 days prior to treatment on study 3. Prior chemotherapy for metastatic pancreatic cancer (other than FOLFIRINOX or adjuvant therapy). 4. History of prior treatment with ipilimumab, antiPD1 antibody, CD137 agonist, or antiCD40 antibody 5. Received any nononcology live vaccine therapy up to one month prior to or after any dose of ipilimumab/vaccine 6. Receiving any other investigational agents 7. Any of the following concomitant therapy: IL2, interferon, immunosuppressive agents, or chronic use of systemic corticosteroids 8. History of symptomatic autoimmune disease or immune impairment. Thyroid disease is allowed. 9. Known brain metastasis 10. Radiographic ascites that is apparent on physical exam or requiring intervention in the 2 months prior to enrollment 11. Uncontrolled intercurrent illness 12. Known or suspected hypersensitivity to GMCSF 13. Chronic HIV, Hepatitis B or Hepatitis C 14. Pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>CTLA-4</keyword>
	<keyword>antibody</keyword>
	<keyword>FOLFIRINOX</keyword>
</DOC>